{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:50:02Z","timestamp":1792227002815,"version":"4.4.0"},"reference-count":99,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health","award":["DK044442"],"award-info":[{"award-number":["DK044442"]}]},{"name":"National Institutes of Health","award":["AA015951"],"award-info":[{"award-number":["AA015951"]}]},{"name":"UH-NEOMED Faculty Scholar funds","award":["DK044442"],"award-info":[{"award-number":["DK044442"]}]},{"name":"UH-NEOMED Faculty Scholar funds","award":["AA015951"],"award-info":[{"award-number":["AA015951"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Type 2 diabetes mellitus (T2DM), often featuring hyperglycemia or insulin resistance, is a global health concern that is increasing in prevalence in the United States and worldwide. A common complication is metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of metabolic syndrome that is also rapidly increasing in prevalence. The majority of patients with T2DM will experience MASLD, and likewise, individuals with MASLD are at an increased risk for developing T2DM. These two disorders may act synergistically, in part due to increased lipotoxicity and inflammation within the liver, among other causes. However, the pathophysiological mechanisms by which this occurs are unclear, as is how the improvement of one disorder can ameliorate the other. This review aims to discuss the pathogenic interactions between T2D and MASLD, and will highlight novel therapeutic targets and ongoing clinical trials for the treatment of these diseases.<\/jats:p>","DOI":"10.3390\/ijms25168731","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T03:46:36Z","timestamp":1723607196000},"page":"8731","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches"],"prefix":"10.3390","volume":"25","author":[{"given":"Shifat-E","family":"Ferdous","sequence":"first","affiliation":[{"name":"Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA"},{"name":"School of Biomedical Sciences, Kent State University, Kent, OH 44242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3691-3330","authenticated-orcid":false,"given":"Jessica M.","family":"Ferrell","sequence":"additional","affiliation":[{"name":"Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA"},{"name":"School of Biomedical Sciences, Kent State University, Kent, OH 44242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ma, R.C.W., and Tong, P.C.Y. (2024). Epidemiology of Type 2 Diabetes. Textbook of Diabetes, Wiley.","DOI":"10.1002\/9781119697473.ch5"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Miao, L., Targher, G., Byrne, C.D., Cao, Y.-Y., and Zheng, M.-H. (Trends Endocrinol. Metab., 2024). Current Status and Future Trends of the Global Burden of MASLD, Trends Endocrinol. Metab., online ahead of print.","DOI":"10.1016\/j.tem.2024.02.007"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A Prospective Study on the Prevalence of NAFLD, Advanced Fibrosis, Cirrhosis and Hepatocellular Carcinoma in People with Type 2 Diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Younossi, Z.M., Golabi, P., Price, J.K., Owrangi, S., Gundu-Rao, N., Satchi, R., and Paik, J.M. (Clin. Gastroenterol. Hepatol., 2024). The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes, Clin. Gastroenterol. Hepatol., online ahead of print.","DOI":"10.1016\/j.cgh.2024.03.006"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-Analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.cgh.2017.04.040","article-title":"Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients with Nonalcoholic Fatty Liver Disease","volume":"15","author":"Hultcrantz","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 Global Prevalence of Nonalcoholic Fatty Liver Disease Using Hierarchical Bayesian Approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing Epidemiology, Global Trends and Implications for Outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rao, G., Peng, X., Li, X., An, K., He, H., Fu, X., Li, S., and An, Z. (2023). Unmasking the Enigma of Lipid Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanism to the Clinic. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1294267"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dezs\u0151, K., Paku, S., K\u00f3bori, L., Thorgeirsson, S.S., and Nagy, P. (2022). What Makes Cirrhosis Irreversible?\u2014Consideration on Structural Changes. Front. Med., 9.","DOI":"10.3389\/fmed.2022.876293"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/1873-3468.12742","article-title":"From Chronic Overnutrition to Metaflammation and Insulin Resistance: Adipose Tissue and Liver Contributions","volume":"591","author":"Caputo","year":"2017","journal-title":"FEBS Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1038\/ncomms8078","article-title":"Hepatic Insulin Signalling Is Dispensable for Suppression of Glucose Output by Insulin in Vivo","volume":"6","author":"Titchenell","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cmet.2013.06.001","article-title":"A Noncanonical, GSK3-Independent Pathway Controls Postprandial Hepatic Glycogen Deposition","volume":"18","author":"Wan","year":"2013","journal-title":"Cell Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin Resistance Drives Hepatic de Novo Lipogenesis in Nonalcoholic Fatty Liver Disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Invest."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.37349\/emed.2020.00019","article-title":"Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Pathophysiological Mechanisms Shared between the Two Faces of the Same Coin","volume":"1","author":"Acierno","year":"2020","journal-title":"Explor. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J. Diabetes Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9084","DOI":"10.3390\/cimb45110570","article-title":"The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease\u2014The Transition from an Adipocentric to Liver-Centric Approach","volume":"45","author":"Macut","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2778","DOI":"10.1097\/MD.0000000000002778","article-title":"Insulin Resistance Is Associated with Total Bile Acid Level in Type 2 Diabetic and Nondiabetic Population: A Cross-Sectional Study","volume":"95","author":"Sun","year":"2016","journal-title":"Medicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.2337\/db13-0639","article-title":"Human Insulin Resistance Is Associated with Increased Plasma Levels of 12\u03b1-Hydroxylated Bile Acids","volume":"62","author":"Haeusler","year":"2013","journal-title":"Diabetes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4093\/dmj.2019.0043","article-title":"Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets","volume":"43","author":"Ferrell","year":"2019","journal-title":"Diabetes Metab. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cmet.2016.01.006","article-title":"FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues","volume":"23","author":"Schlein","year":"2016","journal-title":"Cell Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0904187106","article-title":"FGF21 Induces PGC-1alpha and Regulates Carbohydrate and Fatty Acid Metabolism during the Adaptive Starvation Response","volume":"106","author":"Potthoff","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhao, J., Zhao, Y., Hu, Y., and Peng, J. (2021). Targeting the GPR119\/Incretin Axis: A Promising New Therapy for Metabolic-Associated Fatty Liver Disease. Cell. Mol. Biol. Lett., 26.","DOI":"10.1186\/s11658-021-00276-7"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1096\/fj.15-273771","article-title":"GPR119: A Promising Target for Nonalcoholic Fatty Liver Disease","volume":"30","author":"Yang","year":"2016","journal-title":"FASEB J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction\u2013Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Xu, J., Zhang, D., Mu, X., Shi, Y., Chen, S., Wu, Z., and Li, S. (2021). Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.769069"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhou, R., Lin, C., Cheng, Y., Zhuo, X., Li, Q., Xu, W., Zhao, L., and Yang, L. (2021). Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.600175"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/B978-0-12-398313-8.00006-3","article-title":"Adiponectin and PPAR\u03b3: Cooperative and Interdependent Actions of Two Key Regulators of Metabolism","volume":"Volume 90","author":"Litwack","year":"2012","journal-title":"Adiponectin"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR Control of Metabolism and Cardiovascular Functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential Effects of Selective- and Pan-PPAR Agonists on Experimental Steatohepatitis and Hepatic Macrophages\u2606","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/LVT.0000000000000110","article-title":"Saroglitazar Improves Nonalcoholic Fatty Liver Disease and Metabolic Health in Liver Transplant Recipients","volume":"29","author":"Siddiqui","year":"2023","journal-title":"Liver Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct Effects of Thyroid Hormones on Hepatic Lipid Metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tanase, D.M., Gosav, E.M., Neculae, E., Costea, C.F., Ciocoiu, M., Hurjui, L.L., Tarniceriu, C.C., and Floria, M. (2020). Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165927"},{"key":"ref_38","first-page":"60","article-title":"Resmetirom: An Orally Administered, Small-Molecule, Liver-Directed, \u03b2-Selective THR Agonist for the Treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchEndocrinology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the Treatment of Non-Alcoholic Steatohepatitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/cen.14901","article-title":"The GLP-1 Receptor Agonist Exenatide Reduces Serum TSH by Its Effect on Body Weight in People with Type 2 Diabetes","volume":"99","author":"Tee","year":"2023","journal-title":"Clin. Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin Is Associated with Improvements in Liver Enzymes Potentially Consistent with Reductions in Liver Fat: Results from Randomised Trials Including the EMPA-REG OUTCOME\u00ae Trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wei, Q., Xu, X., Guo, L., Li, J., and Li, L. (2021). Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.635556"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"107492","DOI":"10.1016\/j.intimp.2021.107492","article-title":"The SGLT2 Inhibitor Empagliflozin Negatively Regulates IL-17\/IL-23 Axis-Mediated Inflammatory Responses in T2DM with NAFLD via the AMPK\/MTOR\/Autophagy Pathway","volume":"94","author":"Meng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"155657","DOI":"10.1016\/j.metabol.2023.155657","article-title":"SGLT2 Inhibitor Empagliflozin Downregulates MiRNA-34a-5p and Targets GREM2 to Inactivate Hepatic Stellate Cells and Ameliorate Non-Alcoholic Fatty Liver Disease-Associated Fibrosis","volume":"146","author":"Shen","year":"2023","journal-title":"Metabolism"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/hep4.2069","article-title":"Antifibrotic Effect and Long-term Outcome of SGLT2 Inhibitors in Patients with NAFLD Complicated by Diabetes Mellitus","volume":"6","author":"Arai","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep4.2005","article-title":"Favorable Impact of Long-term SGLT2 Inhibitor for NAFLD Complicated by Diabetes Mellitus: A 5-year Follow-up Study","volume":"6","author":"Akuta","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.dld.2023.01.083","article-title":"SGLT2 Inhibitors Improve Hepatic Fibrosis Assessed by Fibroscan in NAFLD Patients with Type 2 Diabetes: A Five-Year Follow-up Study","volume":"55","author":"Lombardi","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Buchanan, J.L., and Taylor, E.B. (2020). Mitochondrial Pyruvate Carrier Function in Health and Disease across the Lifespan. Biomolecules, 10.","DOI":"10.3390\/biom10081162"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin Sensitizer MSDC-0602K in Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"101178","DOI":"10.1016\/j.molmet.2021.101178","article-title":"Therapeutic Potential of Mitochondrial Uncouplers for the Treatment of Metabolic Associated Fatty Liver Disease and NASH","volume":"46","author":"Goedeke","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S2468-1253(23)00198-X","article-title":"Safety and Efficacy of Once-Daily HU6 versus Placebo in People with Non-Alcoholic Fatty Liver Disease and High BMI: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial","volume":"8","author":"Noureddin","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","article-title":"Efficacy and Safety of PXL770, a Direct AMP Kinase Activator, for the Treatment of Non-Alcoholic Fatty Liver Disease (STAMP-NAFLD): A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Study","volume":"6","author":"Cusi","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pharmthera.2014.02.008","article-title":"Past Strategies and Future Directions for Identifying AMP-Activated Protein Kinase (AMPK) Modulators","volume":"143","author":"Sinnett","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"18572","DOI":"10.1073\/pnas.1417816112","article-title":"Identification of S-Nitroso-CoA Reductases That Regulate Protein S-Nitrosylation","volume":"111","author":"Anand","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1016\/j.cell.2023.11.009","article-title":"An Enzyme That Selectively S-Nitrosylates Proteins to Regulate Insulin Signaling","volume":"186","author":"Zhou","year":"2023","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"155591","DOI":"10.1016\/j.metabol.2023.155591","article-title":"Fructose Induced KHK-C Can Increase ER Stress Independent of Its Effect on Lipogenesis to Drive Liver Disease in Diet-Induced and Genetic Models of NAFLD","volume":"145","author":"Park","year":"2023","journal-title":"Metabolism"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5483\/BMBRep.2018.51.9.197","article-title":"Recent Insights into the Role of ChREBP in Intestinal Fructose Absorption and Metabolism","volume":"51","author":"Lee","year":"2018","journal-title":"BMB Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/dom.14946","article-title":"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics of PF-06835919 in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.medj.2021.04.007","article-title":"Inhibition of Ketohexokinase in Adults with NAFLD Reduces Liver Fat and Inflammatory Markers: A Randomized Phase 2 Trial","volume":"2","author":"Kazierad","year":"2021","journal-title":"Med"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12944-016-0337-x","article-title":"Increased ANGPTL3, 4 and ANGPTL8\/Betatrophin Expression Levels in Obesity and T2D","volume":"15","author":"Cherian","year":"2016","journal-title":"Lipids Health Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6578327","DOI":"10.1155\/2019\/6578327","article-title":"Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes","volume":"2019","author":"Christopoulou","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-Acetyl Galactosamine-Conjugated Antisense Drug to ANGPTL3 MRNA, Lowers Triglycerides and Atherogenic Lipoproteins in Patients with Diabetes, Hepatic Steatosis, and Hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Almeida, C., Monteiro, C., and Silvestre, S. (2021). Inhibitors of 11\u03b2-Hydroxysteroid Dehydrogenase Type 1 as Potential Drugs for Type 2 Diabetes Mellitus\u2014A Systematic Review of Clinical and In Vivo Preclinical Studies. Sci. Pharm., 89.","DOI":"10.3390\/scipharm89010005"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kupczyk, D., Bilski, R., Kozakiewicz, M., Studzi\u0144ska, R., K\u0119dziora-Kornatowska, K., Kosmalski, T., Pedrycz-Wieczorska, A., and G\u0142owacka, M. (2022). 11\u03b2-HSD as a New Target in Pharmacotherapy of Metabolic Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23168984"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2337\/dc09-2315","article-title":"The 11-\u03b2-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.112.192187","article-title":"The Lyn Kinase Activator MLR-1023 Is a Novel Insulin Receptor Potentiator That Elicits a Rapid-Onset and Durable Improvement in Glucose Homeostasis in Animal Models of Type 2 Diabetes","volume":"342","author":"Ochman","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"107555","DOI":"10.1016\/j.jdiacomp.2020.107555","article-title":"A Novel Non-PPARgamma Insulin Sensitizer: MLR-1023 Clinicalproof-of-Concept in Type 2 Diabetes Mellitus","volume":"34","author":"Lee","year":"2020","journal-title":"J. Diabetes Complicat."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Marino, L., Kim, A., Ni, B., and Celi, F.S. (Hepatology, 2023). Thyroid Hormone Action and Liver Disease, a Complex Interplay, Hepatology, online ahead of print.","DOI":"10.1097\/HEP.0000000000000551"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and Safety of the Farnesoid x Receptor Agonist Obeticholic Acid in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a New Efficacy and Safety Analysis of the REGENERATE Trial of Obeticholic Acid for Treatment of Pre-Cirrhotic Fibrosis Due to Non-Alcoholic Steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in Patients with NASH: A Phase II Double-Blind Placebo-Controlled Dose-Ranging Study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X Receptor (FXR): Structures and Ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-8587(16)30155-3","article-title":"Clinical Relevance of the Bile Acid Receptor TGR5 in Metabolism","volume":"5","author":"Scheltema","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Carino, A., Cipriani, S., Marchian\u00f2, S., Biagioli, M., Scarpelli, P., Zampella, A., Monti, M.C., and Fiorucci, S. (2017). Gpbar1 Agonism Promotes a Pgc-1\u03b1-Dependent Browning of White Adipose Tissue and Energy Expenditure and Reverses Diet-Induced Steatohepatitis in Mice. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-13102-y"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1096\/fj.201801373RR","article-title":"Agonism for the Bile Acid Receptor GPBAR1 Reverses Liver and Vascular Damage in a Mouse Model of Steatohepatitis","volume":"33","author":"Carino","year":"2019","journal-title":"FASEB J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"G412","DOI":"10.1152\/ajpgi.00300.2018","article-title":"Intestinal TGR5 Agonism Improves Hepatic Steatosis and Insulin Sensitivity in Western Diet-Fed Mice","volume":"316","author":"Finn","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1210\/jc.2012-4109","article-title":"Effects of Chenodeoxycholic Acid on the Secretion of Gut Peptides and Fibroblast Growth Factors in Healthy Humans","volume":"98","author":"Steinert","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3748\/wjg.v24.i2.195","article-title":"INT-767 Improves Histopathological Features in a Diet-Induced Ob\/Ob Mouse Model of Biopsy-Confirmed Non-Alcoholic Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M. INT-767 Improv","volume":"24","author":"Roth","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Anfuso, B., Tiribelli, C., Adorini, L., and Rosso, N. (2020). Obeticholic Acid and INT-767 Modulate Collagen Deposition in a NASH in Vitro Model. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-58562-x"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Carino, A., Cipriani, S., Marchiano, S., Biagioli, M., Santorelli, C., Donini, A., Zampella, A., Monti, M.C., and Fiorucci, S. (2017). BAR502, a Dual FXR and GPBAR1 Agonist, Promotes Browning of White Adipose Tissue and Reverses Liver Steatosis and Fibrosis. Sci. Rep., 7.","DOI":"10.1038\/srep42801"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Marchian\u00f2, S., Biagioli, M., Morretta, E., Di Giorgio, C., Roselli, R., Bordoni, M., Bellini, R., Urbani, G., Massa, C., and Monti, M.C. (2023). Combinatorial Therapy with BAR502 and UDCA Resets FXR and GPBAR1 Signaling and Reverses Liver Histopathology in a Model of NASH. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-28647-4"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"101152","DOI":"10.1016\/j.molmet.2020.101152","article-title":"FGF19 and FGF21: In NASH We Trust","volume":"46","author":"Talukdar","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in Patients with Non-Alcoholic Steatohepatitis (ALPINE 2\/3): A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100661","DOI":"10.1016\/j.jhepr.2022.100661","article-title":"Effect of Pegbelfermin on NASH and Fibrosis-Related Biomarkers and Correlation with Histological Response in the FALCON 1 Trial","volume":"5","author":"Brown","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2337\/db20-0209","article-title":"The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates","volume":"69","author":"Cui","year":"2020","journal-title":"Diabetes"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile Acids Lower Triglyceride Levels via a Pathway Involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1128\/MCB.01004-12","article-title":"Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes","volume":"33","author":"Caron","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","article-title":"Activation of the Nuclear Receptor FXR Improves Hyperglycemia and Hyperlipidemia in Diabetic Mice","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"eaav9701","DOI":"10.1126\/scitranslmed.aav9701","article-title":"Targeting Diacylglycerol Acyltransferase 2 for the Treatment of Nonalcoholic Steatohepatitis","volume":"11","author":"Amin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-Alcoholic Fatty Liver Disease and Risk of Incident Diabetes Mellitus: An Updated Meta-Analysis of 501 022 Adult Individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8731\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:34:30Z","timestamp":1760110470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":99,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25168731"],"URL":"https:\/\/doi.org\/10.3390\/ijms25168731","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,10]]}}}